{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:45:53Z","timestamp":1761597953984},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1097\/md.0000000000011111","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T17:04:24Z","timestamp":1528909464000},"page":"e11111","source":"Crossref","is-referenced-by-count":3,"title":["Alloreactive cytotoxic T lymphocyte immunotherapy treatment of a patient with metastatic prostate cancer"],"prefix":"10.1097","volume":"97","author":[{"given":"Junfeng","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuetong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-60-20210226","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-60-20210226","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nm.4308","article-title":"VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer","volume":"23","author":"Gao","year":"2017","journal-title":"Nat Med"},{"key":"R3-60-20210226","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ctrv.2017.02.001","article-title":"Prostate cancer heterogeneity: Discovering novel molecular targets for therapy","volume":"54","author":"Ciccarese","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"R4-60-20210226","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002620050405","article-title":"Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2","volume":"45","author":"Kruse","year":"1997","journal-title":"Cancer Immunol Immunother"},{"key":"R5-60-20210226","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1470-8744.1997.tb00433.x","article-title":"Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours","volume":"25","author":"Kruse","year":"1997","journal-title":"Biotechnol Appl Biochem"},{"key":"R6-60-20210226","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1158\/1078-0432.CCR-12-3735","article-title":"Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain","volume":"19","author":"Hickey","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R7-60-20210226","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1097\/01.ju.0000144211.51111.e4","article-title":"Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer","volume":"172","author":"Ragde","year":"2004","journal-title":"J Urol"},{"key":"R8-60-20210226","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/S0022-5347(05)65742-4","article-title":"Gene therapy for prostate cancer: current status and future prospects","volume":"166","author":"Harrington","year":"2001","journal-title":"J Urol"},{"key":"R9-60-20210226","first-page":"225","article-title":"Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance","volume":"37","author":"Alberti","year":"2017","journal-title":"G Chir"},{"key":"R10-60-20210226","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00262-007-0307-2","article-title":"Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus","volume":"56","author":"Mahadevan","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"R11-60-20210226","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/1574892812666170606123113","article-title":"Immune Cells Act as Promising Targets for the Treatment of Bone Metastasis","volume":"12","author":"Luo","year":"2017","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"R12-60-20210226","first-page":"259","article-title":"Redirecting immune cells against bone metastases: Immunotherapy of prostate cancer metastases using genetically programmed immune effector cells","volume":"5","author":"Eshhar","year":"2005","journal-title":"Discov Med"},{"key":"R13-60-20210226","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2008-12-180646","article-title":"Dendritic cell homeostasis","volume":"113","author":"Merad","year":"2009","journal-title":"Blood"},{"key":"R14-60-20210226","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cytogfr.2007.10.003","article-title":"Dendritic cells and cytokines in immune rejection of cancer","volume":"19","author":"Ferrantini","year":"2008","journal-title":"Cytokine Growth Factor Rev"},{"key":"R15-60-20210226","first-page":"3175","article-title":"Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro","volume":"62","author":"Sun","year":"2002","journal-title":"Cancer Res"},{"key":"R16-60-20210226","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00262-003-0415-6","article-title":"Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes","volume":"52","author":"Sun","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"R17-60-20210226","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/cncr.29927","article-title":"A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer","volume":"122","author":"Chow","year":"2016","journal-title":"Cancer"},{"key":"R18-60-20210226","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with 11 bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"R19-60-20210226","first-page":"407","article-title":"The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients","volume":"23","author":"Zullig","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"R20-60-20210226","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R21-60-20210226","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ctrv.2016.02.002","article-title":"Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer","volume":"44","author":"Vignani","year":"2016","journal-title":"Cancer Treat Rev"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000011111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T13:01:49Z","timestamp":1720357309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201806150-00060"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":21,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000011111","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}